SG10201700289RA - Calicheamicin derivative-carrier conjugates - Google Patents

Calicheamicin derivative-carrier conjugates

Info

Publication number
SG10201700289RA
SG10201700289RA SG10201700289RA SG10201700289RA SG10201700289RA SG 10201700289R A SG10201700289R A SG 10201700289RA SG 10201700289R A SG10201700289R A SG 10201700289RA SG 10201700289R A SG10201700289R A SG 10201700289RA SG 10201700289R A SG10201700289R A SG 10201700289RA
Authority
SG
Singapore
Prior art keywords
carrier conjugates
calicheamicin derivative
calicheamicin
derivative
conjugates
Prior art date
Application number
SG10201700289RA
Other languages
English (en)
Inventor
Kunz Arthur
Keith Moran Justin
Thomas Rubino Joseph
Jain Neera
Joseph Vidunas Eugene
Mclean Simpson John
David Robbins Paul
Merchant Nishith
Francis Dijoseph John
Edward Ruppen Mark
Krishnaji Damle Nitin
George Popplewell Andrew
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29401497&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201700289R(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of SG10201700289RA publication Critical patent/SG10201700289RA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/17Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A61K31/175Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46Hybrid immunoglobulins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54F(ab')2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Plant Pathology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
SG10201700289RA 2002-05-02 2003-05-02 Calicheamicin derivative-carrier conjugates SG10201700289RA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37744002P 2002-05-02 2002-05-02

Publications (1)

Publication Number Publication Date
SG10201700289RA true SG10201700289RA (en) 2017-02-27

Family

ID=29401497

Family Applications (3)

Application Number Title Priority Date Filing Date
SG200607459-5A SG165158A1 (en) 2002-05-02 2003-05-02 Calicheamicin derivative-carrier conjugates
SG2011035912A SG187991A1 (en) 2002-05-02 2003-05-02 Calicheamicin derivative-carrier conjugates
SG10201700289RA SG10201700289RA (en) 2002-05-02 2003-05-02 Calicheamicin derivative-carrier conjugates

Family Applications Before (2)

Application Number Title Priority Date Filing Date
SG200607459-5A SG165158A1 (en) 2002-05-02 2003-05-02 Calicheamicin derivative-carrier conjugates
SG2011035912A SG187991A1 (en) 2002-05-02 2003-05-02 Calicheamicin derivative-carrier conjugates

Country Status (34)

Country Link
US (6) US8153768B2 (zh)
EP (3) EP2371392B1 (zh)
JP (5) JP5153057B2 (zh)
KR (2) KR101062628B1 (zh)
CN (1) CN100482277C (zh)
AU (2) AU2003231293A1 (zh)
BE (1) BE2017C049I2 (zh)
BR (3) BR122019027966B8 (zh)
CA (2) CA2871117A1 (zh)
CR (3) CR7557A (zh)
CY (4) CY1116634T1 (zh)
DK (3) DK1507556T3 (zh)
EC (1) ECSP045445A (zh)
ES (3) ES2916174T3 (zh)
FR (1) FR17C1054I2 (zh)
HK (2) HK1162926A1 (zh)
HU (4) HUE027590T2 (zh)
IL (2) IL164946A (zh)
LT (3) LT3127553T (zh)
LU (1) LUC00044I2 (zh)
MX (1) MXPA04010792A (zh)
NL (1) NL300903I2 (zh)
NO (3) NO339730B1 (zh)
NZ (2) NZ586071A (zh)
PH (2) PH12013501159B1 (zh)
PL (5) PL222725B1 (zh)
PT (3) PT1507556T (zh)
RU (3) RU2422157C3 (zh)
SG (3) SG165158A1 (zh)
SI (3) SI3127553T1 (zh)
TW (2) TWI438010B (zh)
UA (1) UA88599C2 (zh)
WO (1) WO2003092623A2 (zh)
ZA (2) ZA200409752B (zh)

Families Citing this family (135)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6905669B2 (en) 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
US20110045005A1 (en) * 2001-10-19 2011-02-24 Craig Crowley Compositions and methods for the treatment of tumor of hematopoietic origin
ES2916174T3 (es) 2002-05-02 2022-06-28 Wyeth Holdings Llc Conjugados de transportador derivado de caliqueamicina
GB0210121D0 (en) 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
TW200539855A (en) * 2004-03-15 2005-12-16 Wyeth Corp Calicheamicin conjugates
WO2005115141A1 (ja) * 2004-05-26 2005-12-08 National University Corporation Kagawa University 希少糖を利用した細胞・組織・臓器保存液及び該液を用いる保存方法
TW200621282A (en) * 2004-08-13 2006-07-01 Wyeth Corp Stabilizing formulations
US7294484B2 (en) 2004-08-27 2007-11-13 Wyeth Research Ireland Limited Production of polypeptides
US7335491B2 (en) 2004-08-27 2008-02-26 Wyeth Research Ireland Limited Production of anti-abeta
TWI364458B (en) 2004-08-27 2012-05-21 Wyeth Res Ireland Ltd Production of tnfr-lg
US20060045877A1 (en) * 2004-08-30 2006-03-02 Goldmakher Viktor S Immunoconjugates targeting syndecan-1 expressing cells and use thereof
AR050642A1 (es) * 2004-09-10 2006-11-08 Wyeth Corp Anticuerpos anti-5t4 humanizados y conjugados anticuerpo anti-5t4/ calicheamicina
EP1661584A1 (en) * 2004-11-26 2006-05-31 Heinz Dr. Faulstich Use of conjugates of amatoxins and phallotoxins with macromolecules for cancer and inflammation therapy
US20110166319A1 (en) * 2005-02-11 2011-07-07 Immunogen, Inc. Process for preparing purified drug conjugates
US7250416B2 (en) 2005-03-11 2007-07-31 Supergen, Inc. Azacytosine analogs and derivatives
US20070003559A1 (en) * 2005-07-01 2007-01-04 Wyeth Methods of determining pharmacokinetics of targeted therapies
NZ565996A (en) 2005-08-16 2011-04-29 Synta Pharmaceuticals Corp Bis(thio-hydrazide amide) formulation
EP2399609B1 (en) 2005-08-24 2015-03-18 ImmunoGen, Inc. Process for preparing maytansinoid antibody conjugates
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
CA2631714C (en) 2005-12-02 2014-09-16 Novartis Ag Nanoparticles for use in immunogenic compositions
BRPI0619476A2 (pt) * 2005-12-05 2011-10-04 Wyeth Corp composições de interleucina-11 e métodos de uso
SG170091A1 (en) 2006-03-10 2011-04-29 Wyeth Corp Anti-5t4 antibodies and uses thereof
EP1859811B1 (en) * 2006-05-27 2011-08-24 Faulstich, Heinz, Dr. Use of conjugates of amatoxins or phallotoxins with macromolecules for tumor and inflammation therapy
PL2041270T3 (pl) 2006-07-13 2014-04-30 Wyeth Llc Wytwarzanie glikoprotein
RU2475478C2 (ru) 2006-08-21 2013-02-20 Синта Фармасьютиклз Корп. Соединения для лечения пролиферативных расстройств
CA2665423A1 (en) * 2006-10-12 2008-04-17 Wyeth Methods and compositions with reduced opalescence
EP2395077A1 (en) 2006-11-03 2011-12-14 Wyeth LLC Glycolysis-inhibiting substances in cell culture
US8481683B2 (en) * 2006-12-01 2013-07-09 Medarex, Inc. Human antibodies that bind CD22 and uses thereof
CA2671900A1 (en) * 2006-12-22 2008-07-03 The Regents Of The University Of California Macromolecular conjugates of cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof
EP2121750A2 (en) * 2007-01-16 2009-11-25 Wyeth Inflammation treatment, detection and monitoring via trem-1
EP2924113B1 (en) * 2007-03-02 2019-04-10 Wyeth LLC Use of copper and glutamate in cell culture for production of polypeptides
ES2642888T3 (es) 2007-05-22 2017-11-20 Wyeth Llc Procedimientos mejorados de fabricación de hidrazidas
PE20090309A1 (es) * 2007-06-04 2009-04-18 Wyeth Corp Conjugado portador-caliqueamicina y un metodo de deteccion de caliqueamicina
US7968687B2 (en) * 2007-10-19 2011-06-28 Seattle Genetics, Inc. CD19 binding agents and uses thereof
CN101945667A (zh) * 2007-12-21 2011-01-12 健泰科生物技术公司 利妥昔单抗不应性类风湿性关节炎患者的疗法
ES2543201T3 (es) * 2007-12-26 2015-08-17 Biotest Ag Métodos y agentes que mejoran la dirección a las células tumorales que expresan CD138
JP5817034B2 (ja) * 2007-12-26 2015-11-18 バイオテスト・アクチエンゲゼルシヤフト Cd138を標的とする免疫複合体及びその使用
RU2537265C2 (ru) 2007-12-26 2014-12-27 Биотест Аг Агенты против клетки-мишени, нацеленные на cd138, и их применение
JP2011507933A (ja) * 2007-12-26 2011-03-10 バイオテスト・アクチエンゲゼルシヤフト 免疫複合体の細胞傷害性副作用の低減及び有効性の改善方法
US20090186026A1 (en) * 2008-01-18 2009-07-23 Wyeth Ephrin and eph receptor agonists for modulation of bone formation and resorption
US8591889B2 (en) * 2008-04-04 2013-11-26 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Human monoclonal antibodies specific for CD22
FR2930443B1 (fr) 2008-04-29 2010-06-25 Oreal Produit extemporane de soin a base d'un lyophilisat de microorganisme et de tensioactif(s) de hlb superieur ou egal a 12
KR20220035504A (ko) * 2008-04-30 2022-03-22 이뮤노젠 아이엔씨 가교제 및 그 용도
KR102560218B1 (ko) * 2009-06-03 2023-07-26 이뮤노젠 아이엔씨 접합 방법
US20130012916A1 (en) * 2010-02-11 2013-01-10 Glide Pharmaceutical Technologies Limited Delivery of immunoglobulin variable domains and constructs thereof
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
CA2807607A1 (en) 2010-08-20 2012-02-23 Wyeth Llc Cell culture of growth factor-free adapted cells
EP2857499A1 (en) 2010-10-01 2015-04-08 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
WO2012065161A2 (en) 2010-11-12 2012-05-18 Scott & White Healthcare Antibodies to tumor endothelial marker 8
US8512679B2 (en) * 2011-03-04 2013-08-20 Elwha Llc Glassy compositions
EP2691155B1 (en) 2011-03-29 2018-11-14 Immunogen, Inc. Preparation of maytansinoid antibody conjugates by a one-step process
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
SG2014013395A (en) 2011-08-30 2014-05-29 Astex Pharmaceuticals Inc Decitabine derivative formulations
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RU2648950C2 (ru) 2011-10-03 2018-04-02 Модерна Терапьютикс, Инк. Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение
EP2768944B2 (en) 2011-10-21 2023-11-22 Pfizer Inc. Addition of iron to improve cell culture
EP2788030B1 (en) 2011-12-08 2018-06-20 Biotest AG Uses of immunoconjugates targeting cd138
LT2791160T (lt) 2011-12-16 2022-06-10 Modernatx, Inc. Modifikuotos mrnr sudėtys
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
WO2013151667A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
SG11201408626YA (en) 2012-07-03 2015-03-30 Univ Washington Antibodies to tau
US8883979B2 (en) 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
WO2014055877A1 (en) 2012-10-04 2014-04-10 Immunogen, Inc. Use of a pvdf membrane to purify cell-binding agent cytotoxic agent conjugates
JP6133431B2 (ja) 2012-11-24 2017-05-24 ハンジョウ ディーエーシー バイオテック シーオー.,エルティディ.Hangzhou Dac Biotech Co.,Ltd. 親水性連結体及び薬物分子と細胞結合分子との共役反応における親水性連結体の使用
EP2922554B1 (en) 2012-11-26 2022-02-23 ModernaTX, Inc. Terminally modified rna
KR20210132742A (ko) 2012-12-21 2021-11-04 알트루바이오 인코퍼레이티드 친수성 자기-희생 링커 및 그것의 포합체
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
MY192404A (en) * 2013-05-02 2022-08-19 Hoffmann La Roche Combination therapy of an afucosylated cd20 antibody with a cd22 antibody-drug conjugate
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
EP3052521A1 (en) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
CN105828841A (zh) 2013-11-04 2016-08-03 辉瑞大药厂 抗-efna4抗体-药物缀合物
CN105683159B (zh) * 2013-11-04 2017-12-19 辉瑞大药厂 用于合成加利车霉素衍生物的中间体和方法
WO2015127685A1 (en) 2014-02-28 2015-09-03 Hangzhou Dac Biotech Co., Ltd Charged linkers and their uses for conjugation
WO2015140708A1 (en) 2014-03-19 2015-09-24 Pfizer Inc. Method of cell culture
US11998594B2 (en) 2014-04-02 2024-06-04 Case Western Reserve University Anti-cancer plant virus particles linked to HER2 antigens
SG11201610620UA (en) 2014-06-20 2017-01-27 Bioalliance Cv Anti-folate receptor aplha (fra) antibody-drug conjugates and methods of using thereof
TW202136296A (zh) 2014-06-27 2021-10-01 美商C2N醫療診斷有限責任公司 人類化抗-tau抗體
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
US9925281B2 (en) 2014-08-05 2018-03-27 Case Western Reserve University Coated plant virus imaging agents
CN107001428B (zh) 2014-11-07 2023-01-10 卡斯西部储备大学 使用病毒颗粒的癌症免疫疗法
KR102701678B1 (ko) 2015-04-07 2024-08-30 메모리얼 슬로안 케터링 캔서 센터 나노입자 면역컨쥬게이트
AR104333A1 (es) * 2015-04-21 2017-07-12 Stemcentrx Inc Constructos de calicheamicina y métodos de uso
GB201506870D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
JP6688551B2 (ja) 2015-05-21 2020-04-28 ハープーン セラピューティクス,インク. 三重特異性結合タンパク質と使用方法
EP3313527B1 (en) 2015-06-29 2021-02-24 Case Western Reserve University Anticancer drug-containing plant virus particles
BR112018000054A2 (pt) 2015-07-02 2018-09-04 Otsuka Pharmaceutical Co., Ltd. composições farmacêuticas liofilizadas
JP6759326B2 (ja) 2015-07-12 2020-09-23 ハンジョウ ディーエーシー バイオテック シーオー.,エルティディ.Hangzhou Dac Biotech Co.,Ltd. 細胞結合分子の共役のための架橋連結体
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
GB201601077D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
GB201601073D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
EP3322485B1 (en) 2015-07-16 2020-07-01 Case Western Reserve University Plant virus particles for delivery of antimitotic agents
GB201601075D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies molecules
CA3214798A1 (en) 2015-09-23 2017-03-30 Pfizer Inc. Cells and method of cell culture
EP3374493A1 (en) 2015-11-09 2018-09-19 Bristol-Myers Squibb Company Methods to manipulate quality attributes of polypeptides produced in cho cells
TWI753875B (zh) 2016-01-08 2022-02-01 美商美國全心醫藥生技股份有限公司 四價抗psgl-1抗體及其用途
WO2017172907A1 (en) * 2016-03-29 2017-10-05 Sorrento Therapeutics, Inc. Calicheamicin antibody drug conjugates linking an amidoacetyl group to a sugar moiety on calicheamicin
CN109415688B (zh) 2016-04-05 2022-08-02 辉瑞公司 细胞培养工艺
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
GB201610512D0 (en) 2016-06-16 2016-08-03 Autolus Ltd Chimeric antigen receptor
EP3487527A4 (en) 2016-07-21 2020-03-11 Case Western Reserve University PARTICLES OF VEGETABLE OR VIRAL-LIKE PARTICLES
US11654117B2 (en) 2016-11-03 2023-05-23 Case Western Reserve University Melt processed viral nanoparticle constructs
AU2016429272A1 (en) 2016-11-14 2019-05-02 Hangzhou Dac Biotech Co., Ltd. Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers
US11590183B2 (en) 2017-03-10 2023-02-28 Case Western Reserve University Cancer immunotherapy using virus particles
WO2018167621A1 (en) 2017-03-16 2018-09-20 Pfizer Inc. Tyrosine prototrophy
EP3621994A4 (en) 2017-05-12 2020-12-30 Harpoon Therapeutics, Inc. MESOTHELINE BINDING PROTEINS
US11672840B2 (en) 2017-05-17 2023-06-13 Case Western Reserve University Anticancer trail-targeted plant virus particles
BR112020002280A2 (pt) 2017-08-03 2020-07-28 Otsuka Pharmaceutical Co., Ltd. composto farmacológico e métodos purificação do mesmo
US20200255785A1 (en) 2017-09-15 2020-08-13 Bristol-Myers Squibb Company Online biomass capacitance monitoring during large scale production of polypeptides of interest
BR112020007249B1 (pt) 2017-10-13 2022-11-22 Harpoon Therapeutics, Inc Roteína de ligação a antígeno de maturação de célula b, proteína de ligação multiespecífica e uso das referidas proteínas
US11739301B2 (en) 2017-10-27 2023-08-29 Case Western Reserve University Tymovirus virus and virus-like particles as nanocarriers for imaging and therapeutic agents
WO2019178489A1 (en) 2018-03-16 2019-09-19 Bristol-Myers Squibb Company Metabolic enzyme activity and disulfide bond reduction during protein production
CN110507824A (zh) * 2018-05-21 2019-11-29 荣昌生物制药(烟台)有限公司 一种抗间皮素抗体及其抗体药物缀合物
RU2770474C1 (ru) * 2018-05-30 2022-04-18 ЭББВИ СТЕМСЕНТРКС ЭлЭлСи Конъюгаты антитело к sez6-лекарственное средство и способы применения
CA3114038A1 (en) 2018-09-25 2020-04-02 Harpoon Therapeutics, Inc. Dll3 binding proteins and methods of use
KR20210116437A (ko) 2018-11-20 2021-09-27 코넬 유니버시티 방사성핵종의 마크로사이클릭 복합체 및 암의 방사선 요법에서의 이의 용도
US20220073942A1 (en) 2018-12-06 2022-03-10 Pfizer Inc. Cells with reduced inhibitor production and methods of use thereof
AU2020242284A1 (en) 2019-03-19 2021-09-16 Fundació Privada Institut D'investigació Oncològica De Vall Hebron Combination therapy for the treatment of cancer
US11390853B2 (en) 2019-04-26 2022-07-19 Case Western Reserve University Freeze dried viral nanoparticle constructs
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
US11896676B2 (en) 2019-08-07 2024-02-13 Case Western Reserve University Targeting cancer cells and tissue using filamentous plant virus particles
EP4069312A4 (en) * 2019-12-04 2024-03-27 The Research Foundation for the State University of New York COMPOSITIONS AND METHODS FOR REDUCING OFF-TARGET TOXICITY OF ANTIBODY-DRUG CONJUGATES
AU2021306613A1 (en) 2020-07-07 2023-02-02 BioNTech SE Therapeutic RNA for HPV-positive cancer
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
TW202245808A (zh) 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性rna
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
CN112724263B (zh) * 2021-04-02 2021-08-03 上海偌妥生物科技有限公司 改造抗cd20单克隆抗体以提高其药物疗效的方法及其应用
MX2024000674A (es) 2021-07-13 2024-02-07 BioNTech SE Agentes de union multiespecificos contra cd40 y cd137 en terapia de combinacion.
TW202333802A (zh) 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性rna(二)
WO2023148598A1 (en) 2022-02-02 2023-08-10 Pfizer Inc. Cysteine prototrophy
WO2024058201A1 (ja) * 2022-09-16 2024-03-21 国立研究開発法人量子科学技術研究開発機構 放射性医薬組成物の中間体の製造方法、放射性医薬組成物の中間体の精製用キット
WO2024089013A1 (en) 2022-10-25 2024-05-02 Peptomyc, S.L. Combination therapy for the treatment of cancer
WO2024126457A1 (en) 2022-12-14 2024-06-20 Astellas Pharma Europe Bv Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors
WO2024218706A1 (en) 2023-04-21 2024-10-24 Pfizer Inc. Improved cells and cell cultures

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4970198A (en) 1985-10-17 1990-11-13 American Cyanamid Company Antitumor antibiotics (LL-E33288 complex)
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4771128A (en) * 1986-10-10 1988-09-13 Cetus Corporation Method of purifying toxin conjugates using hydrophobic interaction chromatography
US5037651A (en) 1987-01-30 1991-08-06 American Cyanamid Company Dihydro derivatives of LL-E33288 antibiotics
US5079233A (en) 1987-01-30 1992-01-07 American Cyanamid Company N-acyl derivatives of the LL-E33288 antitumor antibiotics, composition and methods for using the same
US5053394A (en) 1988-09-21 1991-10-01 American Cyanamid Company Targeted forms of methyltrithio antitumor agents
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5134075A (en) 1989-02-17 1992-07-28 Oncogen Limited Partnership Monoclonal antibody to novel antigen associated with human tumors
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
ATE207075T1 (de) 1990-06-27 2001-11-15 Univ Princeton Sonden für die detektion der p53 mutante
DK0531472T3 (da) 1991-03-06 2003-12-01 Merck Patent Gmbh Humaniserede monoklonale antistoffer
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5686072A (en) 1992-06-17 1997-11-11 Board Of Regents, The University Of Texas Epitope-specific monoclonal antibodies and immunotoxins and uses thereof
US5484892A (en) * 1993-05-21 1996-01-16 Dana-Farber Cancer Institute, Inc. Monoclonal antibodies that block ligand binding to the CD22 receptor in mature B cells
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
US5436265A (en) 1993-11-12 1995-07-25 Merck Frosst Canada, Inc. 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents
US6310185B1 (en) 1994-03-08 2001-10-30 Memorial Sloan Kettering Cancer Center Recombinant human anti-Lewis Y antibodies
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
ES2158048T5 (es) 1994-08-12 2009-11-04 The University Of Utah Research Foundation Mutaciones del gen ligado al cromosoma 17q, de susceptibilidad al cancer de mama y de ovario.
JP3053873B2 (ja) 1994-08-12 2000-06-19 イムノメディクス,インコーポレイテッド B細胞リンパ腫細胞および白血病細胞に特異的な免疫結合体およびヒト化抗体
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5712374A (en) * 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
US20020141990A1 (en) 1996-11-01 2002-10-03 Smithkline Beecham Corporation Anti-RSV human monoclonal antibodies
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
ATE383430T1 (de) 1997-03-20 2008-01-15 Us Gov Health & Human Serv Rekombinante antikörper und immunkonjugate gezielt auf cd22-tragende zellen und tumoren
US6306393B1 (en) * 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US6183744B1 (en) 1997-03-24 2001-02-06 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
DK0999853T3 (da) 1997-06-13 2003-04-22 Genentech Inc Stabiliseret antostofformulering
AT408613B (de) 1998-06-17 2002-01-25 Immuno Ag Pharmazeutisches faktor vii-präparat
US6183477B1 (en) * 1998-09-04 2001-02-06 Smith & Nephew, Inc. Attachment tool for drill guide
KR100345463B1 (ko) 1998-11-19 2003-01-08 주)녹십자 B형간염바이러스의표면항원프리-s1에대한인간화항체및이의제조방법
JP2000226336A (ja) * 1998-11-30 2000-08-15 Sankyo Co Ltd 免疫グロブリン製剤
PT1137941E (pt) 1998-12-10 2009-10-15 Brystol Myers Squibb Company Esqueletos de proteínas para compostos miméticos de anticorpos e outras proteínas de ligação
EP2289551A1 (en) * 1999-06-09 2011-03-02 Immunomedics, Inc. Immunotherapy of autoimmune disorders using antibodies which target B-cells
WO2001012653A1 (en) * 1999-08-17 2001-02-22 Novo Nordisk A/S Stabilisation of freeze-dried cake
CN1382259A (zh) 1999-10-12 2002-11-27 康奈科斯优化研究和发展有限公司 检测粪便中抗酸微生物的改进方法
US20010046496A1 (en) 2000-04-14 2001-11-29 Brettman Lee R. Method of administering an antibody
GB0013810D0 (en) 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
ES2916174T3 (es) * 2002-05-02 2022-06-28 Wyeth Holdings Llc Conjugados de transportador derivado de caliqueamicina
GB0210121D0 (en) * 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products

Also Published As

Publication number Publication date
NO344509B1 (no) 2020-01-20
ZA201003874B (en) 2019-12-18
US20160303252A1 (en) 2016-10-20
EP1507556A2 (en) 2005-02-23
UA88599C2 (ru) 2009-11-10
HUS1700038I1 (hu) 2017-11-28
IL164946A (en) 2015-06-30
NL300903I2 (nl) 2018-02-08
JP5756489B2 (ja) 2015-07-29
US20040082764A1 (en) 2004-04-29
BR122019027966B8 (pt) 2021-07-27
CY2017035I1 (el) 2018-04-04
CY1116634T1 (el) 2017-03-15
RU2422157C3 (ru) 2021-04-23
JP2012051900A (ja) 2012-03-15
SI3127553T1 (sl) 2022-02-28
ES2545745T3 (es) 2015-09-15
PT1507556T (pt) 2016-09-28
NO20044663L (no) 2005-01-25
IL230659A (en) 2016-02-29
BR0309868A (pt) 2005-10-18
BRPI0309868B8 (pt) 2021-05-25
PH12013501158A1 (en) 2015-11-09
PL224844B1 (pl) 2017-02-28
TW201231089A (en) 2012-08-01
WO2003092623A2 (en) 2003-11-13
PL224001B1 (pl) 2016-11-30
FR17C1054I2 (fr) 2019-01-11
TW200404005A (en) 2004-03-16
PL228741B1 (pl) 2018-05-30
BR122019027974B1 (pt) 2022-06-14
LTPA2017036I1 (lt) 2017-11-27
JP2017105801A (ja) 2017-06-15
ES2916174T3 (es) 2022-06-28
LUC00044I1 (zh) 2017-11-03
CR20120364A (es) 2012-10-05
US20040192900A1 (en) 2004-09-30
IL230659A0 (en) 2014-03-31
TWI379693B (en) 2012-12-21
US20120213804A1 (en) 2012-08-23
CY2017035I2 (el) 2018-04-04
KR20050006220A (ko) 2005-01-15
DK3127553T3 (da) 2022-01-31
SI1507556T1 (sl) 2016-10-28
US20180339058A1 (en) 2018-11-29
JP2013163678A (ja) 2013-08-22
PL410219A1 (pl) 2015-03-30
JP5441971B2 (ja) 2014-03-12
SI2371392T1 (sl) 2015-10-30
AU2009202609B2 (en) 2012-07-26
US20140235835A1 (en) 2014-08-21
RU2004135101A (ru) 2005-06-27
CA2871117A1 (en) 2003-11-13
PL413302A1 (pl) 2016-05-23
TWI438010B (zh) 2014-05-21
RU2011108928A (ru) 2012-09-20
HK1162926A1 (zh) 2012-09-07
PT3127553T (pt) 2022-01-24
US8153768B2 (en) 2012-04-10
PL410218A1 (pl) 2015-03-30
LUC00044I2 (zh) 2018-02-26
PH12013501159A1 (en) 2015-12-02
ECSP045445A (es) 2005-01-28
BRPI0309868B1 (pt) 2020-04-28
PH12013501159B1 (en) 2015-12-02
ZA200409752B (en) 2010-08-25
LTC2371392I2 (lt) 2019-03-25
NO2017061I1 (no) 2017-11-21
HUE030806T2 (hu) 2017-05-29
HUE027590T2 (hu) 2016-11-28
CN1665532A (zh) 2005-09-07
RU2602878C3 (ru) 2021-11-24
CY1124900T1 (el) 2023-01-05
RU2422157C2 (ru) 2011-06-27
JP2005524700A (ja) 2005-08-18
NZ573563A (en) 2010-10-29
HUE057124T4 (hu) 2022-02-28
LT3127553T (lt) 2022-04-11
CA2483552A1 (en) 2003-11-13
IL164946A0 (en) 2005-12-18
NO339730B1 (no) 2017-01-23
KR101062628B1 (ko) 2011-09-07
MXPA04010792A (es) 2005-03-07
EP3127553A1 (en) 2017-02-08
US8747857B2 (en) 2014-06-10
EP1507556B1 (en) 2016-07-27
BR122019027966B1 (pt) 2020-11-17
EP2371392A1 (en) 2011-10-05
CY1117973T1 (el) 2017-05-17
PH12013501158B1 (en) 2015-11-09
JP5153057B2 (ja) 2013-02-27
PL411824A1 (pl) 2015-08-17
AU2009202609A1 (en) 2009-07-16
RU2678818C2 (ru) 2019-02-04
RU2602878C2 (ru) 2016-11-20
PL224150B1 (pl) 2016-11-30
HK1070825A1 (zh) 2005-06-30
EP2371392B1 (en) 2015-07-08
US8835611B2 (en) 2014-09-16
CR7557A (es) 2008-10-03
AU2003231293A1 (en) 2003-11-17
JP6872376B2 (ja) 2021-05-19
NZ586071A (en) 2012-02-24
CR20130390A (es) 2013-11-08
LT1507556T (lt) 2016-10-10
WO2003092623A3 (en) 2004-03-18
KR101125524B1 (ko) 2012-03-22
NO20161431A1 (no) 2005-01-25
RU2016141576A (ru) 2018-05-03
SG187991A1 (en) 2013-03-28
EP1507556A4 (en) 2009-01-07
DK2371392T3 (en) 2015-08-31
HUE057124T2 (hu) 2022-04-28
ES2593304T3 (es) 2016-12-07
US9351986B2 (en) 2016-05-31
EP3127553B1 (en) 2021-12-01
BE2017C049I2 (zh) 2022-08-09
RU2016141576A3 (zh) 2018-05-03
SG165158A1 (en) 2010-10-28
JP2015061875A (ja) 2015-04-02
KR20110050753A (ko) 2011-05-16
DK1507556T3 (en) 2016-09-12
CN100482277C (zh) 2009-04-29
PL222725B1 (pl) 2016-08-31
FR17C1054I1 (zh) 2018-01-12
PT2371392E (pt) 2015-10-07
PL374523A1 (en) 2005-10-31

Similar Documents

Publication Publication Date Title
HUS1700038I1 (hu) Calicheamicin származék-hordozó konjugátumok
EP1608735A4 (en) RNAI CONJUGATES
AU2003276494A8 (en) Functional sites
HUE058897T2 (hu) Polimer VIII-as faktor egység konjugátumok
AU2003253048A1 (en) Tubulysin conjugates
EP1482957A4 (en) ANTIBIOTIC CONJUGATES
GB0209896D0 (en) Conjugate
AU2003278857A8 (en) Oligonucleotide conjugates
GB0119665D0 (en) Conjugates
ZA200500199B (en) Immunogenic conjugates
GB0221778D0 (en) Conjugate
AU2003292197A8 (en) Lna-cpg conjugates
GB0217672D0 (en) Powerdrive
GB0426103D0 (en) Retention mechanism
AU7426601A (en) Gene-regulating conjugates
IL163551A0 (en) Antibiotic conjugates
GB0211890D0 (en) Device II
GB0226009D0 (en) Envelopes
GB0102530D0 (en) Tidal rater
GB0208542D0 (en) Guide